EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208

M Hatziapostolou; C Polytarchou

doi:10.1111/bph.12718

EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208

Br J Pharmacol. 2015 Sep;172(18):4597-4599. doi: 10.1111/bph.12718.

Authors

M Hatziapostolou¹, C Polytarchou¹

Affiliation

¹ Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Abstract

This article is a Commentary on Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195-5208. doi: 10.1111/bph.12669.

Keywords: EPH receptors; angiogenesis inhibitors; cancer; ephrins.